Aug 22, 2025 • Motley Fool
NEUTRAL
Why Recursion Pharmaceuticals Stock Caught a Cold This Week
The few news items from and about the company weren't all that positive.
Aug 10, 2025 • Motley Fool
SOMEWHAT-BULLISH
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
These companies are in the right place at the right time with the right products.
Aug 06, 2025 • Zacks Commentary
NEUTRAL
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
Aug 05, 2025 • Motley Fool
NEUTRAL
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.
Aug 05, 2025 • Motley Fool
NEUTRAL
Recursion ( RXRX ) Q2 Revenue Jumps 33%
Recursion Pharmaceuticals ( NASDAQ:RXRX ) , a technology-driven biotech company decoding biology using artificial intelligence for drug discovery, released its financial results for the second quarter of 2025 on August 5, 2025.
Aug 05, 2025 • Benzinga
NEUTRAL
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion reports second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million. Recursion reports a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share. The market's back, and these 3 income stocks are thriving. See them here→